GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of the GTS400 trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma or ocular hypertension and co-existing cataract.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Detailed Description
Glaucoma is a collection of disorders characterized by progressive loss of visual field due to optic nerve damage. It is a leading cause of blindness in the United States, affecting 1-2% of individuals aged 60 and over. Management of glaucoma requires chronic, life-long treatment with a spectrum of therapeutic options including medications, laser treatment and surgical implants. The common goal among the various therapies is to lower intraocular pressure to target levels in order to prevent loss of visual fields from excessive pressure on the optic nerve.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Cataract Surgery Only
|
Procedure: Cataract Surgery
Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
|
Experimental: Treatment with Cataract Surgery & Stents Ab interno trabecular micro-bypass stent surgery |
Device: iStent Inject (GTS400)
Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Proportion of subjects with 12 month diurnalIOP </= 21 mmHg without use of ocular hypotensive medications for >/= 4 weeks prior to 12 month visit. [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosed with open-angle glaucoma in the study eye
-
Subject must be on 1 to 3 glaucoma medications
-
Subject able and willing to attend follow up visits for two years postop
-
Subject able and willing to sign informed consent
Exclusion Criteria:
-
Pseudoexfoliative and pigmentary glaucoma
-
Prior glaucoma surgery of any type
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Boozman-Hof Regional Eye Clinic | Rogers | Arkansas | United States | 72756 |
2 | North Bay Eye Associates, Inc. | Petaluma | California | United States | 94954 |
3 | Glaucoma Consultants of Colorado | Parker | Colorado | United States | 80134 |
4 | The Center for Excellence in Eye Care | Miami | Florida | United States | 33176 |
5 | International Eye Center | Tampa | Florida | United States | 33603 |
6 | Clayton Eye Center / Eye Care Centers Management, Inc. | Morrow | Georgia | United States | 30260 |
7 | Chicago Eye Specialists | Chicago | Illinois | United States | 60619 |
8 | Whitson Vision, PC | Indianapolis | Indiana | United States | 46240 |
9 | D'Ambrosio Eye Care | Lancaster | Massachusetts | United States | 01523 |
10 | Kresge Eye Institute | Detroit | Michigan | United States | 48201 |
11 | Discover Vision Centers | Independence | Missouri | United States | 64055 |
12 | Silverstein Eye Centers | Kansas City | Missouri | United States | 64133 |
13 | St. John's Medical Research Institute | Springfield | Missouri | United States | 65807 |
14 | Las Vegas Physician Research Group | Henderson | Nevada | United States | 75965 |
15 | Shepherd Eye Center | Las Vegas | Nevada | United States | 89121 |
16 | Ophthalmic Consultants of Long Island | Rockville Center | New York | United States | 11570 |
17 | Thomas Mundorf, MD | Charlotte | North Carolina | United States | 28204 |
18 | Laurel Eye Clinic | Brookville | Pennsylvania | United States | 15825 |
19 | Carolina Eyecare Physicians | Mt. Pleasant | South Carolina | United States | 29464 |
20 | Vance Thompson Vision / Sanford Clinic | Sioux Falls | South Dakota | United States | 57105 |
21 | Texan Eye | Austin | Texas | United States | 78731 |
22 | Lehmann Eye Center | Nacogdoches | Texas | United States | 75965 |
Sponsors and Collaborators
- Glaukos Corporation
Investigators
- Study Director: Jeff Wells, PharmD, MBA, Glaukos Corporation
- Study Chair: Jay Katz, MD, Wills Eye Institute; Thomas Jefferson University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GC-006